IL-6 Receptor Blockers Show Promise for Preventing Relapses in Rare Autoimmune Neurological Disorder MOGAD
核心洞察
An international Mayo Clinic-led study published in JAMA Neurology found IL-6 receptor (搜索) blockers tocilizumab and satralizumab substantially reduced relapses in MOGAD (搜索) patients.
The observational study evaluated 116 patients across multiple centers in North and South America, making it the largest real-world evaluation of IL-6 receptor (搜索) blockade in MOGAD (搜索) to date.
No therapies are currently approved specifically for preventing MOGAD (搜索) relapses, and these findings offer guidance while randomized clinical trials remain underway.
An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising therapeutic option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD (搜索)), a rare autoimmune neurological disorder that can cause vision loss, paralysis, and other serious neurological complications. The findings, published in JAMA Neurology, represent one of the largest real-world evaluations to date of IL-6 receptor (搜索) blockade in this patient population and offer new evidence to help guide treatment decisions while randomized clinical trials are underway.
MOGAD (搜索) occurs when the immune system mistakenly attacks myelin, the protective coating surrounding nerve fibers in the brain, spinal cord, and optic nerves. In some patients, the disease causes repeated inflammatory attacks, or relapses, that can lead to accumulating neurological disability. Although several therapies are used off-label, there are currently no treatments approved specifically for preventing relapses in MOGAD.
Study Design and Scope
Researchers evaluated 116 patients treated with IL-6 receptor (搜索) blockers across multiple centers in North and South America, making it the largest observational study of its kind. The study focused on two medications: tocilizumab, which is widely available around the world and was received by most participants, and satralizumab, which was administered to a smaller number of patients. Both belong to the class of drugs known as IL-6 receptor blockers.
The immune signaling protein IL-6 is believed to play an important role in the inflammation that damages myelin in people diagnosed with MOGAD (搜索). By blocking that immune signaling pathway, these medications are designed to reduce inflammation and help prevent future relapses.
Key Findings and Clinical Implications
The study found that patients had substantially fewer relapses after starting treatment with IL-6 receptor (搜索) blockers. The medications also demonstrated a generally favorable safety profile, though infections remain an important consideration for clinicians.
"Interleukin-6 receptor blockers appear to be a promising treatment option for people living with MOGAD (搜索)," said Eoin Flanagan, M.B., B.Ch., a neurologist at Mayo Clinic and senior author of the study. "While we await results from randomized clinical trials, these findings provide additional evidence that these medications may help limit the neurological disability that can accumulate with repeated attacks."
The Power of Multinational Collaboration
Because MOGAD (搜索) is uncommon, individual medical centers often care for relatively small numbers of patients, making it difficult to study new treatments. This multinational collaboration allowed researchers to evaluate outcomes across various patient populations while expanding the evidence base for IL-6 receptor (搜索) blockade in MOGAD.
"Rare diseases require collaboration," said Andreu Vilaseca Jolonch, M.D., first author of the study and a neurology fellow at Mayo Clinic. "By bringing together patients and researchers across multiple countries, we were able to generate stronger evidence than any single center could produce alone. That collaboration not only strengthened this study but also created a foundation for future research."
Looking Forward
Multiple clinical trials evaluating treatments for MOGAD (搜索) are underway, and observational studies such as this one help provide important evidence while physicians await those results. "There is growing optimism for patients with MOGAD," Dr. Flanagan added. "New treatments are emerging, and we're trying to bring the best treatment options to patients while continuing to learn which therapies work best."
This research was supported by the National Institutes of Health (R01NS113828). One patient included in the study was supported by National Institutes of Health grant R01AI170863-01A1.